Hypericin-d10

CAT:
804-HY-N0453S
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Hypericin-d10 - image 1

Hypericin-d10

  • UNSPSC Description:

    Hypericin-d10 is the deuterium labeled Hypericin. Hypericin is a photosensitive antiviral with anticancer and antidepressant agent derived from Hypericum perforatum. It can inhibit tyrosine kinases with IC50 of 7.5 μM.
  • Target Antigen:

    Apoptosis; Influenza Virus; Isotope-Labeled Compounds
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Anti-infection;Apoptosis;Others
  • Field of Research:

    Cancer
  • Purity:

    95.32
  • Solubility:

    DMSO : 250 mg/mL (ultrasonic;warming)
  • Smiles:

    O=C1C2=C(O)C([2H])=C(O)C3=C2C4=C(C5=C6C(O)=C([2H])C(C([2H])([2H])[2H])=C5C7=C4C1=C(O)C([2H])=C7C([2H])([2H])[2H])C8=C3C(O)=C([2H])C(O)=C8C6=O
  • Molecular Weight:

    514.50
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Agostinis P et al. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol. 2002 Mar;34(3):221-41.|[3]Lenard J et al. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses usinghypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):158-62.|[4]Hwang MS et al. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin. Anticancer Res. 2001 Jul-Aug;21(4A):2649-55.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    No Development Reported